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KESAN EKSTRAK GYNURA PROCUMBENS TERHADAP ENZIM 
METABOLISME DRUG 
 
ABSTRAK 
 
 Kebangkitan penggunaan ubat-ubatan herba di seluruh dunia, dan 
penggunaan bersama drug konvensional dan terapi tradisional telah menjadi 
kebiasaan. Gynura procumbens ialah herba malar hijau yang lazimnya dimakan 
secara mentah atau diminum sebagai teh di Malaysia. Walaupun pelbagai kajian 
mengenai aktiviti farmakologi Gynura procumbens telah dijalankan, interaksi di 
antara herba ini dengan enzim metabolisme drug masih tidak diketahui. Ini adalah 
kajian pertama berkaitan dengan modulasi ekstrak Gynura procumbens terhadap 
enzim metabolisme drug. Pengekstrakan daun Gynura procumbens  dengan air, 
etanol dan metanol masing-masing menghasilkan peratusan hasil sebanyak 27.50%, 
7.80% dan 4.20%. Kuantifikasi dua sebatian penanda kaempferol-3-O-rutinosida dan 
astragalin di dalam setiap ekstrak adalah berjaya kecuali ekstrak akueus Gynura 
procumbens. Setiap ekstrak etanol dan metanol masing-masing mengandungi 
kaempferol-3-O-rutinosida dan astagalin sebanyak 1.60% dan 1.79% dan 2.33% dan 
3.83%. Bagaimanapun, kaempferol-3-O-rutinosida dan astragalin tidak dapat dikenal 
pasti di dalam ekstrak akueus. Kandungan sebatian fenolik di dalam ekstrak Gynura 
procumbens boleh disenaraikan dalam turutan menurun seperti berikut: metanol > 
etanol > akueus, manakala kandungan sebatian flavonoid di dalam ekstrak Gynura 
procumbens boleh disenaraikan dalam turutan menurun seperti etanol >metanol > 
akueus. Ekstrak metanol menunjukkan penghapus radikal bebas yang paling aktif 
berbanding ekstrak lain.  
xxv 
 
Ekstrak etanol menunjukkan kesan perencatan yang kuat terhadap enzim CYP3A4, 
CYP1A2 dan GST masing-masing dengan nilai IC50 32.01 ± 1.11 µg/mL, 7.87 ± 1.22 
µg/mL dan 44.62 ± 1.12 µg/mL. Bagaimanapun, ekstrak etanol tidak menunjukan 
perencatan yang ketara terhadap enzim UGT. Ekstrak methanol menunjukkan kesan 
perencatan yang lemah terhadap enzim CYP3A4, CYP1A2 dan GST masing-masing 
dengan nilai IC50 lebih daripada 100 µg/mL. Ekstrak metanol juga tidak menjejaskan 
enzim UGT. Ekstrak akueus sebaliknya, tidak menunjukkan kesan perencatan 
terhadap semua enzim yang dikaji. Kesimpulannya, perencatan enzim metabolisme 
drug mengikut turutan kandungan sebatian flavonoid (ekstrak etanol > ekstrak 
metanol > ekstrak akueus) iaitu semakin tinggi kandungan sebatian flavonoid, 
semakin kuat perencatan enzim metabolisme drug.  
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THE EFFECTS OF GYNURA PROCUMBENS EXTRACTS ON DRUG 
METABOLIZING ENZYMES 
 
ABSTRACT 
 
 Resurgence in the use of herbal medicines worldwide and the co-use of 
conventional drug and traditional therapies is becoming more common. Gynura 
procumbens is an evergreen herb that has been commonly eaten raw or drink as tea 
in Malaysia. Despite various studies conducted on the pharmacological activities of 
Gynura procumbens, the interaction between this herb with drug metabolizing 
enzymes is still unknown. This is the first study regarding the modulation of Gynura 
procumbens extracts towards drug metabolizing enzymes. Extraction of Gynura 
procumbens leaves with water, ethanol and methanol produced a percentage of yields 
of 27.50%, 7.80% and 4.20% respectively. Quantification of two marker compounds 
kaempferol-3-O-rutinoside and astragalin in each extracts is successful except for the 
aqueous extract of Gynura procumbens. Each ethanol and methanol extracts contain 
1.60% and 1.79% and 2.33% and 3.83% of kaempferol-3-O-rutinoside and astragalin 
respectively. Kaempferol-3-O-rutinoside and astragalin, however, could not be 
identified in aqueous extract. The content of phenolic compounds in Gynura 
procumbens extracts can be ranked in decreasing order as methanol extract > ethanol 
extract > aqueous extract, whereas the content of flavonoid compounds in Gynura 
procumbens extracts can be ranked in decreasing order as follows: ethanol extract > 
methanol extract > aqueous extract.  
 
xxvii 
 
The methanol extract of Gynura procumbens exhibited the most active free radical 
scavenger compared to the other extracts. Ethanol extract exhibited strong inhibitory 
effect on CYP3A4, CYP1A2 and GST enzyme with IC50 values of 32.01 ± 
1.11µg/mL, 7.87 ± 1.22µg/mL and 44.62 ± 1.12µg/mL respectively. However, 
ethanol extract did not show significant inhibition on UGT enzymes. Methanol 
extract exhibited weak inhibitory effect on CYP3A4, CYP1A2 and GST enzymes 
with IC50 values more than 100 µg/mL. Similar to ethanol extract, methanol extract 
also did not affect UGT enzymes. Aqueous extract, on the other hand, demonstrated 
no inhibitory effect on all enzymes studied. In conclusion, the inhibition of drug 
metabolizing enzymes in this study follows the rank order of total flavonoid content 
(ethanol extract > methanol extract > aqueous extract) in which the higher the total 
flavonoid content, the stronger the inhibition of drug metabolizing enzymes studied.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background of the study 
Herbal medicine has gained great attention throughout the world. Herbal medicine is 
defined as a medicine which is made from plants, including seeds, berries, roots, 
leaves, bark. Herb plants have been used for medicinal treatment as early as 3,000 
BC by the ancients Chinese and Egyptians. Africans and native Americans have also 
used herbs in their healing rituals while the Indians practiced the use of herbs in 
Ayurveda treatment, which is a system of traditional Indian medicine (TIM) 
(Patwardhan et al., 2005). In the latest issue of Herbal Gram, American Botanical 
Council reported herbal supplement sales in all channels reached up to $5.3 billion in 
the United States in 2011, which is an increase of 4.3% of the total sales in 2010 
(Schultz, 2012). Herbal medicine has been receiving continuous overwhelming 
response from all over the world because it is safe, sustainable, readily available (can 
be eaten raw) and it is an alternative medicine to conventional drug which is usually 
expensive. In the year 1994, U.S. Dietary Supplement Health and Education Act 
(DSHEA) have classified herbal medicine as ‘dietary supplement’. As a result, herbal 
medicines, unlike prescription drug, can be sold without prior safety and 
effectiveness tests and if the U.S Food and Drug Administration (FDA) prove a 
particular herbal medicine as harmful and dangerous for human consumption, only 
then it will be removed from the market (Brent and Bauer, 2003).  
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There is huge demand for herbal medicinal plants from pharmaceutical companies, 
phytopharmaceutical companies, health product companies, traditional and 
alternative practitioners due to their great medical and health benefits. Currently, 
there are 40 top-selling herbal dietary supplements in the United States and cranberry 
(Vaccinium macrocarpon) is the best-selling herbal product in the year of 2011, 
followed by, saw palmetto (Serenoa repens), soy (Glycine max), ginkgo (Ginkgo 
biloba), garlic (Allium sativum), milk thistle (Silybum marianum) and so forth 
(Blumenthal et al., 2012). Ginkgo (Ginkgo biloba) is believed to heal memory 
impairment, stroke, edema, inflammation, Alzheimer’s disease and vasso oclusive 
crisis (Diamond et al., 2000) while garlic (Allium sativum) is suggested to have 
antilipidemic, antihypertensive, antiglycemic and antithrombotic properties 
(Ackermann et al., 2001). Echinacea or purple coneflower (Echinacea purpurea) is 
commonly used to treat influenza and common cold in the United States. Besides 
that, ginseng (Panax ginseng), another traditional herbal plant widely used in the 
United States is known to enhanced human immune system, increase physical 
stamina and decrease fatigueness (Foti and Wahlstrom, 2008). Although herbal 
medicine promises a great deal of benefits health care, a large number of 
investigations have reported its adverse side effects and possible fatality in some 
cases. Herbal medicine usually contains a mixture of more than one active 
ingredient. Interactions between herbal medicine and its corresponding active 
constituents towards drug metabolizing enzyme are summarized in Table 1.1.  
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Table 1.1: Interactions between herbal medicines and drug metabolizing enzymes. 
 
Herbal medicines Scientific Name Active constituent Interaction References 
Black cohosh Actaea racemosa Triterpene glycoside Inhibit CYP2D6 Gurley et al., 2005 
Angelica root Angelica dahurica Furanocoumarin derivatives 
Inhibit CYP2C, 2D1 and 
3A 
Ishihara et al., 2000 
Black pepper Piper nigrum Alkaloid piperine Inhibit CYP3A4 Bhardwaj et al., 2002 
Grapefruit juice Citrus paradisi 
Bergamottin, 6’7’-
dihydroxybergamottin 
Inhibit 1A2, 2A6, 2C9, 
2C19, 2D6, 2E1 and 3A4 
He et al., 1998 
Kava Piper methysticum Kavalactones 
Inhibit CYP1A, 2C9, 
2C19, 3A4 and 2D6 
Foster et al., 2003 
Milk thistle Silybum marianum Silymarin 
Decrease bilirubin 
conjugation 
Salmi and Sarna, 1982 
St. John’s wort Hypericum perforatum Hypericin, hyperforin 
Inhibit CYP1A2, 2C9, 
2C19, 2D6 and 3A4 
Wang et al., 2001 
Soy Glycine max Daidzein, genistein CYP3A4 Foster et al., 2003 
Saw palmetto Serenoa repens 
Fatty acid, plant sterols, 
flavonoids 
Inhibit CYP3A4, 
2D6,2C9 
Yale et al., 2005 
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Table 1-1. Continued. 
 
Herbal medicines Scientific Name Active constituent Interaction References 
Schisandra fruit Schisandra chinensis Schisandrin, gomisin Inhibit CYP3A4 Iwata et al., 2004 
Valerian Valeriana officinalis 
Valerenic acid, valepotriates, 
alkaloids, furanofuran lignans, 
free amino acids 
Inhibit 2C19, 2D6 and 
3A4 
Strandell et al., 2004 
Licorice Glycyrrhiza glabra Glycyrrhizin Inhibit CYP3A4 Budzinski et al., 2000 
Hempedu bumi Andrographis paniculata Andrographalide Inhibit UGT2B7 Zainal Abidin et al., 2014 
Misai Kucing Orthosiphon stamineus 
Sinensetin, eupatorin, rosmarinic 
acid 
Inhibit GST Tan et al., 2011 
Temu lawak Curcuma xanthorrhiza 
Curcumin, curcumene, 
xanthorrhizol 
Inhibit UGT1A1 and 2B7 Mohd Salleh., 2015 
Kratom Mitragyna speciosa Mitragynine Weakly inhibit GST Azizi et al., 2010 
Cranberry Vaccinium oxycoccos 
Anthocyanins, flavonols, 
quercetin 
Inhibit CYP3A Uesawa et al., 2006 
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For example, grapefruit juice contains two of the most abundant furanocoumarins, 
namely bergamottin and 6’,7’-dihydroxybergamottin, which are known to be 
responsible for herb-drug interaction (Zhou et al., 2004). Milk thistle (Silybum 
marianum) contains flavonolignans, which are present as multiple structural isomers 
including silymarin, and flavonolignans have been evalueted to inhibit Phase I drug 
metabolizing enzyme at low concentration (Foti and Wahlstrom, 2008). Piperine, the 
active chemical constituent that can be found in Piper nigrum Linn and Piper 
Longum Linn, is responsible for raising the concentration of several drugs in blood 
plasma such as phenytoin (antiepileptic drug), propanolol (drug used to treat high 
blood pressure) and theophylline (drug used to treat respiratory disease). It is also 
increased the plasma concentration of rifampicin in patients with pulmonary 
tuberculosis (Hu et al., 2005). Garlic (Allium sativum) is reported to have several of 
compounds such as allicin and alliin, flavonoids, polysaccharides, prostaglandins, 
saponins and terpenes. Some reports have stated the co-administration of warfarin 
with garlic extract increases the clotting time and international normalised ratio and 
result in spontaneous spinal epidural haematoma and postoperative bleeding (Hu et 
al., 2005).  
Gynura procumbens which is known as Sambung Nyawa in Malaysia is widely 
distributed in South East Asian countries. Gynura procumbens leaves have been used 
traditionally to treat various diseases. Many researchers reported that this herbal 
plant exhibited pharmacological potential as anti-diabetic, anti-inflammatory, anti-
hypertensive and more (Hassan et al., 2010; Lee et al., 2012; Iskander et al., 2002; 
Kim et al., 2006).  
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Despite numerous studies on the various pharmacological effects of Gynura 
procumbens, its inhibitory effects on drug metabolizing enzymes have not been 
investigated to date. Hence, the present study was carried out to expand the study on 
the effects of varying Gynura procumbens extracts on drug metabolizing enzymes 
activities. Quantification of two marker compounds using a high performance liquid 
chromatography (HPLC) method and standardization of Gynura procumbens extracts 
by biological profiling (determination of total phenolic and flavonoid content, and 
antioxidant activity) were also carried out. The experiments of the present study were 
summarized in Figure 1.1. 
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Figure 1.1: The experimental design for the effects of Gynura procumbens extracts on drug metabolizing enzymes study. 
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1.2 The Problem Statement of the Study 
Gynura Procumbens have been used traditionally to treat various types of diseases. It 
is also have been studied extensively by researchers to investigate the pharmacology 
properties of Gynura procumbens so that this plant can be a natural and non-toxic 
medication for diseases for example in treating diabetes patient. Since Gynura 
procumbens has been eaten or drank for medicinal purposes, it is crucial to 
investigate the effect of this herbal plant on drug metabolizing enzymes to predict 
any changes in drug metabolizing enzymes activity which may lead to serious side 
effects. 
 
1.3 The Purpose of the Study 
The aim of the study is to investigate the effects of Gynura procumbens extracts on 
Phase I and Phase II drug metabolizing enzymes. 
 
1.4 The Objectives of the Study 
The objectives of the present study are: 
1. To quantify the amount of two marker compounds (kaempferol-3-O-
rutinoside and astragalin) in each extract of Gynura procumbens. 
2. To study the total phenolic content, total flavonoid content and DPPH 
scavenging activity of each extracts of Gynura procumbens. 
3. To evaluate the effect of Gynura procumbens extracts on human recombinant 
CYP3A4 and CYP1A2 enzymes isoforms respectively by using luciferin 
derivatives as the marker reaction for CYP3A4 and CYP1A2 enzymes 
activity. 
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4. To study the effect of Gynura procumbens extract on rat liver microsomes 
(RLM) UDP-glucuronosyltransferases (UGT) enzyme by employing p-
nitrophenol (p-NP) as the marker reaction for UGT enzyme activity. 
5. To study the effect of Gynura procumbens extract on rat liver cytosolic 
fraction glutathione S-transferases (GST) enzyme by employing 1-chloro-2,4-
dinitrobenzene (CDNB) as the marker reaction for GST enzyme activity. 
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CHAPTER TWO 
 
LITERATURE REVIEWS 
 
2.1 Description of Gynura procumbens 
Gynura procumbens (Figure 2.1) is an annual evergreen shrub of the Compositae 
family which can be found in Indonesia, Thailand, and Malaysia. Gynura 
procumbens is locally known in Malaysia as ‘Akar Sebiak’, ‘Kecam Akar’ or 
‘Sambung Nyawa’ (Bhore and Vaishana, 2010). It is factual that the leaves of 
Gynura procumbens are not bitter at all and it can be eaten raw as salad. Gynura 
procumbens is mostly used by the Malays in Malaysia as salad. They also can be 
sun-dried, preserved as tea. The tea can be prepared by steeping the leaves of Gynura 
procumbens in boiled water for about 5 minutes and it is ready to be consumed either 
hot or cold. Honey or sugar can be added to reduce the bitterness of Gynura 
procumbens tea. Gynura procumbens also sold over-the-counter in capsule form 
especially in Indonesia (Figure 2.1).  
 
Figure 2.1: Gynura procumbens 
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Figure 2.2: Capsule of Gynura procumbens sold in the market. Pictures are adopted 
from panels (a) www.sambungnyawa.com; (b) www.etalasemuslim.com; and (c) 
www.istanaherbal.com.  
 
2.2 Taxonomy of Gynura procumbens 
Kingdom : Plantae 
Division : Magnoliophyta 
Class : Magnoliopsida 
Order : Asterales 
Family : Asteraceae 
Genus : Gynura 
Species : Gynura procumbens 
 
 
 
 
 
 
 
A B C 
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2.3 Pharmacological Potentials of Gynura procumbens 
Gynura procumbens is traditionally used to treat various types of illnesses such as 
fever, rash inflammation, kidney disease, hemorrhoids and diabetes mellitus (Kim et 
al., 2006; Saiman et al., 2012).  
The leaves of Gynura procumbens are proven to be non-toxic (Yam et al., 2009) and 
they exhibited anti-diabetic (Hassan et al., 2010; Lee et al., 2012), anti-oxidative 
(Puangpronpitag et al., 2010), anti-inflammatory (Iskander et al., 2002), and anti-
hypertensive characteristics (Kim et al., 2006). Ethanol extract of Gynura 
procumbens may also have biguanide-like activity since it is shown to reduced serum 
cholesterol and triglyceride levels when an optimum dose was given over a period of 
a group of diabetic rats (Zhang and Tan, 2000). Gynura procumbens has been 
demonstrated to decrease blood pressure in spontaneously hypertensive rats via the 
inhibition of the angiotensin-converting enzyme (Hoe et al., 2007).  
However, the same author has proposed butanolic fraction of Gynura procumbens 
may contribute to hypotensive effect in rats via other mechanism. The investigation 
has reported butanolic fraction of Gynura procumbens resulted in lowered blood 
pressure (hypotensive effect) in rats as a result of vasodilation due to inhibition of 
Ca
2+
 influx via receptor-operated and/or voltage-dependent calcium channel (Hoe et 
al., 2007). In addition, ethanol extract of Gynura procumbens inhibited MMP-1 and 
MMP-9 expressions which are induced by UVB irradiation via the inhibition of pro-
inflammatory cytokine mediator release and reactive oxygen species (ROS) 
production (Kim et al., 2011).  
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Ethanol extract of Gynura procumbens is also shown to have antiproliferative 
activity on male rat’s livers induced by 7,12-dimethylbenz[α]anthracene (Nisa et al., 
2012). According to Nurulita (2012) in her recent study, ethyl acetate fraction of 
Gynura procumbens in combination with doxorubicin (DOX) potentiate DOX effect 
on breast cancer cell growth inhibition and hence this fraction could be developed as 
co-chemotherapy agent in reversing multidrug resistance.  
 
2.4 Phytochemical constituents of Gynura procumbens 
Numerous studies have exposed that Gynura procumbens leaves extract contains 
various active compounds such as flavanoids, saponins, sterol glycoside, terpenoids 
and tannins (Zahra et al., 2011). Previous studies have demonstrated that Gynura 
procumbens which extracted using various concentration of ethanol as extraction 
solvent (95%, 75%, 50%, 25%, and 0% of ethanol (% v/v)) with different extraction 
methods (Soxhlet, maceration and ultra-sonication) showed vary in phenolic content 
(Algariri et al., 2013).  
The total content of phenolic compounds in various extracts of Gynura procumbens 
is ranked in decreasing order as 50% ethanol > 75% ethanol > 95% ethanol > 25% 
ethanol > 0% ethanol. However, total flavonoid content of Gynura procumbens was 
found to decrease with the increase in polarity of the extraction solvent (Algariri et 
al., 2013). Crude methanol extract of Gynura procumbens and its fractions 
(chloroform, ethyl acetate, n-butanol, and aqueous) had showed different level of 
antioxidant potential. Ethyl acetate fraction exhibited the highest antioxidant 
properties compared to the other extracts and fractions.  
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2.5 Phytochemical Analysis of Gynura procumbens 
The chemical constituents of Gynura procumbens that is responsible for its 
antioxidant action was determined using HPTLC and it is found that the content of 
astragalin and kaempferol-3-O-rutinoside were relatively high in the ethyl acetate 
fraction (Yam et al., 2008). Three components from Gynura procumbens ethanol 
extract (quercetin 3-O-rutinoside, isobioquercetin and kaempferol 3-O-rutinoside) 
have also been identified by direct comparison of their respective molecular weights 
and retention time using mass spectrophotometer and high performance liquid 
chromatography (HPLC) (Kim et al., 2011). Akowuah et al. (2001, 2002) conducted 
preliminary phytochemical analysis on Gynura procumbens methanol extract, and 
this analysis led to isolation of flavonol and flavonol glycoside including rutin, 
quercetin, kaempferol, and quercetin-3-O-rhamnosyl (1-6) glucoside, quercetin-3-O-
rhamnosyl (1-6) galactoside, kaempferol-3-O-rhamnosyl 1-6) glucoside and 
kaempferol-3-O-glucoside.  
In addition, kaempferol-3-O-rutinoside and kaempferol-3-O-glucoside in the Gynura 
procumbens methanol extract both have been determined using high performance 
thin layer chromatography (Yam et al., 2009). Hassan et al. (2010) performed the 
same phytochemical analysis as Yam et al. (2009) towards Gynura procumbens 
aqueous extract and revealed that this plant extract contains 0.76% and 2.65% of 
kaempferol-3-O-rutinoside and kaempferol-3-O-glucoside respectively.  
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2.6 Drug Metabolism 
Preclinical drug metabolism and pharmacokinetics is important in drug discovery 
and development (Gunaratna, 2000). Drug metabolism is defined as a process of 
elimination of foreign compound from the body. This process occurs mainly in the 
liver with the aid of enzymes. Enzymes which are responsible for converting or 
transforming or detoxifying foreign compound are called drug metabolizing 
enzymes. Drug metabolizing enzymes are separated into two groups including 
oxidative drug metabolizing enzymes and conjugative drug metabolizing enzymes. 
Oxidative drug metabolizing enzymes are also known as Phase I drug metabolizing 
enzymes includes cytochrome P450 (CYP450) and flavin monooxygenase (FMO), in 
which both catalyze the introduction of an oxygen atom into substrate molecules 
resulting in hydroxylation and demethylation. Phase I reaction involves the process 
of converting non-polar parent compound into a more polar or hydrophilic compound 
by the addition of functional groups such as –OH, -SH, -NH2, -COOH.  
 
The conjugative drug metabolizing enzymes or Phase II drug metabolizing enzymes 
include UDP-glyconosyltransferases (UGTs), glutathione transferases (GSTs), 
sulfotransferases (SULTs), and N-acetyltransferases (NATs). Phase II drug 
metabolism reaction involves the conjugation or the attachment of an ionized group 
to the substrate which then further increases aqueous solubility and decreases 
pharmacological activity of the substrate. This group comprises of glutathione, 
methyl group and acetyl group.  
 
 
16 
 
Phase I reaction occurs in liver microsome and usually precede Phase II reaction 
which takes place in the liver cells as the parent compound or the metabolite from 
Phase I becomes conjugated. Numerous factors are knowns to affect drug 
metabolism reaction including enzyme induction and enzyme inhibition. Enzyme 
induction results in acceleration of drug biotransformation and as a result loses its 
therapeutic effects due to rapid metabolism. In worst cases, certain drugs with active 
metabolites can exhibit increased adverse drug effects and/or toxicity. On the other 
hand, enzyme inhibition occurs when two drugs are metabolized via the same 
pathway and if one of the resulting drug products is a potent inhibitor, it can decrease 
the metabolism of the other drug thus leading to adverse toxicity (Ogu and Maxa, 
2000). There are several factors that influence the activity of drug metabolism 
(Gibson and Skett, 1986) and these factors are summarized in Table 2.1 below. 
 
Table 2.1: List of factors that affect the activity of drug metabolizing enzymes 
Internal External 
Species Diet 
Genetic  Environment 
Sex  
Age  
Hormonal control  
Disease  
*Adapted from Gibson and Skett, (1986) 
 
To date, drug metabolism is one of the most intensely studied aspects in herb-drug 
interaction. Grapefruit juice has been found to disrupt the oral bioavailability of 
various CYP3A4 substrates including cyclosporin A, felodipine, midazolam, 
terfenadine, verapamil, saquinavir, and ethinyl estradiol (Schmiedlin-Ren et al., 
1997). 
17 
 
In addition, Bhardwaj et al. (2002) reported that, piperine, a chemical constituent 
found in black pepper inhibited P-glycoprotein-mediated, polarized transport of 
digoxin and cyclosporin A transport in monolayers of Caco-2 cells (Bhardwaj et al., 
2002). The same author also claimed that piperine inhibited CYP3A4-mediated 
formation of the verapamil metabolites D-617 and norverapamil (Bhardwaj et al., 
2002). Since P-glycoprotein and CYP3A4 are important in determination of 
bioavailability of many drugs such as digoxin, verapamil and cyclosporin A, 
inhibition of both proteins by concomitantly administered substance such as piperine 
or grapefruit juice may lead to elevation of plasma concentration of a drug due to a 
dual effect on drug transport and metabolism (Schmiedlin-Ren et al., 1997; Bhardwaj 
et al., 2002). 
 
2.7 Phase I Drug Metabolizing Enzymes 
Cytochrome P450 or CYP450 isoenzymes are superfamilies of hemoproteins. The 
term P450 is derived from spectrophotometric absorption peak of the enzyme at a 
wavelength 450 nm when it is bounded and reduced by carbon monoxide (Chang and 
Kam, 1999). CYP450 isoenzymes are popular for their role in the metabolism of 
diverse exogenous materials such as drugs, environmental pollutants, and chemicals 
(Guengerich, 1999). Fifty seven CYP450 genes have been found in human and only 
CYP1, CYP2, and CYP3 families are known to mainly contribute to drug 
metabolism. Among CYP450 isoenzymes, only five accounts for major drug 
metabolism namely CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 
(Guengerich, 2003). CYP3A4 is the most important enzyme as it metabolizes almost 
all CYP450-mediated reactions (Guengerich, 1996).
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Generally, xenobiotic compounds are removed from our body by oxidation reaction 
of CYP450 which then results in the formation of more water-soluble and less toxic 
metabolite. However, metabolic activation of carcinogens may also occur during the 
oxidative mechanism mediated by CYP enzymes (Gonzalez and Gelboin, 1994).
 
For 
instance, CYP1 family is responsible for the metabolic activation of carcinogens 
such as benzo[α]pyrene and 7,12-dimethylben[α]anthracene (Slaga et al., 1979). 
Therefore, inhibitor of CYP1A2 may possess chemo preventive properties (Kim et 
al., 2013).
 
Several studies have been conducted regarding herbal and natural 
constituents that have inhibitory effects on CYP1A family and these constituents 
may play as chemopreventive agents in carcinogenesis due to exposure to polycyclic 
aromatic hydrocarbon (PAH) (Hwang et al., 2008; Pekthong et al., 2008).
 
 
 
Pharmacological studies have reported kava extract and/or kavalactones, potent 
inhibitors of CYP3A4, may decrease elimination of alprazolam upon co-
administeration of kava and alprazolam (Zhou et al., 2004).
 
Other studies have 
reported that tanshinones, an active constituent in Danshen, (Salvia miltiorrhiza) 
inhibited various CYP probe substrates in both human liver microsomes and specific 
human isoforms in vitro (Wang et al., 2010).
 
In addition, drug interaction has also 
been observed for the two known chemical constituents in Schisandra fruit extract 
(gomisin B and C) that showed a potent inhibitory effect on CYP3A4 activity 
comparable with that of ketoconazole, a known inhibitor for CYP3A4 enzyme (Iwata 
et al., 2004). Natural product has been consumed for different reasons. The leaves of 
Mitragyna speciosa or commonly known as ketum in Malaysia, have been used 
tradionally to treat various diseases.  
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However, recent studies revealed that alkaloid extract of Mitragyna speciosa is a 
potent inhibitor of CYP3A4 and CYP2D6 and moderate inhibitor of CYP1A2 (Kong 
et al., 2011).
 
 
 
2.8 CYP3A4 Isoform 
The literature data on CYP3A4 inhibition by herbal medicines has increased over the 
years. Goldenseal (Hydrastis canadensis), St John’s wort (Hypericum perforatum), 
cat’s claw (Uncaria tomentosa), Black samson (Echinacea angustifolia), wild cherry 
(Trifolium pratense), chamomile (Matricaria chamomilla) and licorice (Glycyrrhiza 
glabra) significantly inhibited CYP3A4 metabolite with IC50 values lower than 1% to 
2% of full strength (highest concentration) measured using fluorometric microtitre 
plate assay (Budzinski et al., 2000). Herbal components namely ginsenosides Rb1, 
Rb2, Rc, and Rd (from ginseng quercetin) and ginkgolides A and B (from Ginkgo 
biloba) were investigated for their inhibitory effect on CYP2C9 and CYP3A4 and all 
these herbal components showed different potencies in inhibiting both the CYPs (He 
and Edeki, 2004). Hyperforin, a putative active antidepressant constituent from St 
John’s wort (Hypericum perforatum) extract was a potent competitive inhibitor of 
CYP3A4 activities with the inhibitor constant (Ki) value of 0.48µM (Obach, 2000). 
Ethanol extract of kava and three purified kava lactones including methysticin, 
desmethoxyyangonin, and yangonin were previously investigated for their inhibitory 
effects on CYP450 enzymes (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1 and CYP3A4) expressed in a baculovirus / insect cell system and in 
cryopreserved human hepatocytes and it is found that they have IC50 values 
approximately 10µM (Zou et al., 2004).  
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By employing P450-Glo
TM
 Screening System, Alpine lovage (Mutellina purpurea 
L.) methanol extract showed about 6 fold significant inhibition towards CYP3A4 
compared to its aqueous extract (Sieniawska et al., 2012). In a cell-free system, 
schisandrol A (SCH) and gomisin A (GOM), two main dibenzocyclooctadiene 
lignants isolated from the fruit of Schisandra chinensis, inhibited CYP3A4 activity 
with IC50 value 32.02µM and 1.39µM respectively (Wan et al., 2010).  
 
Four Malaysian medicinal plants namely Andrographis paniculata, Orthosiphon 
staminues, Mitragyna speciosa and Curcuma xanthorrhiza have been found to have 
the ability to inhibit CYP3A4 with IC50 value in the range from 28µg/mL to 
300µg/mL (Hanapi et al., 2010). Earlier studies reported that, Orthosiphon stamineus 
dichloromethane and petroleum ether extract moderately inhibited CYP3A4 than 
aqueous and methanol, but eupatorin, the active constituent of Orthosiphon 
staminues was found potently inhibited CYP3A4 (Pan et al., 2011). In addition, the 
same author suggested that the inhibitory effect of dichloromethane and petroleum 
ether extract on CYP3A4 was probably because of the high content of eupatorin in 
dichloromethane and petroleum ether extracts and therefore, drug-herb interaction 
are likely to occur for CYP3A4 substrates (Pan et al., 2011). It is worth noting that, 
among 30 Indonesian medicinal plants, 4 medicinal plants (ethyl acetate soluble 
fraction), namely Pi. cuceba, Pi. nigrum fruit, Pi nigrum leaf, and Z. aromaticum  
showed inhibitory activity of more than 70% towards CYP3A4 (Usia et al., 2006). 
Interestingly, (-) -hinokinin, a compound that contain two methylenedioxyphenyl in 
its chemical structure, isolated from Pi. Cuceba, is a potent inhibitor towards 
CYP3A4 and therefore, the inhibitory effect of Pi. Cuceba on CYP3A4 may be due 
to this compound (Usia et al., 2006). 
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In contrast to Usia et al. (2006), schisandria fruit component which is schizandrin, a 
compound with no methylenedioxy group in its chemical structure, weakly inhibited 
CYP3A4 with an IC50 value more than 100µM
 
(Iwata et al., 2004). 
 
It is noteworthy that, perturbation in CYP450 enzyme activities may lead to 
treatment failure or worse, clinically fatal due to toxicity (Gomez-Lechon et al., 
2008).
 
Inhibition or induction of CYP450 enzymes may increase the drug plasma 
concentration level in the body. This situation may lead to toxicity or decrease the 
drug plasma concentration therefore, loses its therapeutic effect which may lead to 
treatment failure (Li et al., 1997). Based on the recent studies on Elephantopus 
scaber L. major constituent, a series of CYP induction and CYP inhibition have been 
done using P450 Glo
TM
 CYP3A4 assay. Deoxyelephantopin (major germacranolide 
sesquiterpene lactone isolated from E. Saber) showed induction of CYP3A4 enzyme 
activity at a concentration range of 0.01 – 0.1µM. Oddly, when the concentration 
was further increased, CYP3A4 enzyme activity starts to decrease and thus, 
deoxyelephantopin was found to be a weak inducer and a weak inhibitor and unlikely 
to stimulate negative effect in human (Koe et al., 2013). It can be conclude that, if a 
drug/herb inhibits CYP3A4 that catalyzes the metabolism of a concomitant drug, 
plasma concentration of the concomitant drug will increase and thus, this will lead to 
toxicity. Table 2.2 shows the list of CYP3A4 substrates that may cause herb-drug 
interaction or drug-drug interaction when CYP3A4 inhibitors are taken concurrently 
with herbal medicines. 
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Table 2.2: List of CYP3A4 substrates 
CYP3A4 substrates 
Alfentanil (Alfenta) Carbamazepine (eg, Tegretol) Erythromycin Solifenacin (Vesicare) 
Alfuzosin (Uroxatral) Clonazepam (Klonopin) Estazolam (ProSom) Tinidazole (Tindamax) 
Atorvastatin (Lipitor) Cyclosporine (Neoral) Ethosuximide (Zarontin) Tipranavir (Aptivus) 
Amlodipine (Norvasc) Darunavir (Prezista) Felodipine (Plendil) Triazolam (Halcion) 
Bexarotene (Targretin) Dexamethasone (Decadron) Flurazepam (Dalmane) Verapamil (Calan) 
Budesonide (Entocort) Docetaxel (Taxotere) Galantamine (Reminyl) Vinblastine (Velbane) 
Buprenorphine (Subutex) Ergotamine (Ergomar) Gefitinib (Iressa) Vincristine (Oncovin) 
Halofantrine (Halfan) Indinavir (Crixivan) Irinotecan (Camptosar) Ziprasidone (Geodon) 
Itraconazole (Sporanox) Lopinavir (Kaletra) Levomethadyl (Orlaam) Zolpidem (Ambien) 
Lovastatin (Mevacor) Midazolam (Versed) Nefazodone Zonisamide (Zonegran) 
Paclitaxel (Taxol) Pioglitazone Ranolazine (Ranexa) Zopiclone (Imovane) 
Repaglinide (Prandin) Ritonavir (Norvir) Simvastatin (Zocor) Sildenafil (Viagra) 
Adapted from Horn and Hansten (2008) 
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2.9 CYP1A2 Isoform 
CYP1A2 is one of the members of CYP450 enzymatic group and its expression is 
induced by certain polycyclic aromatic hydrocarbons (PAHs). It has the ability to 
metabolize some PAHs into carcinogenic intermediates. The main CYP450 enzymes 
involved in carcinogen activation are CYP1A1, CYP1A2, CYP1B1, CYP2A6, 
CYP2E1 and CP3A4. The most common enzymes from group CYP450 involved in 
cancer induction are both CYP1A2 and CYP2A6 (Guengerich, 2003). Several 
studies have been conducted exclusively regarding the issue that some herbal or 
natural constituents have the capability to inactivate CYP1A family members thus 
playing an important role in preventing the effects in carcinogenesis due to exposure 
to PAHs (Hwang et al., 2008; Pekthong et al., 2008).
 
Standardized Asian ginseng 
(Panax ginseng) extract and standardized North American ginseng (Panax 
quinquefolius) extract inhibited human recombinant enzymes CYP1A1, CYP1A2, 
and CYP1B1 activities in a concentration-dependent manner (Chang et al., 2002). 
Mollugin, a pharmacological compound isolated from Rubia cordifolia, inhibited 
recombinant enzyme CYP1A2 competitively thus changing the pharmacokinetic 
properties of other drugs such as caffeine and theophylline inevitably (Kim et al., 
2013). Tanshinones (tanshinones I, tanshinone IIA, and cryptotanshinone), major 
constituents of Salvia miltiorrhiza, competitively inhibited CYP1A2 with a Ki value 
of 1.5 – 2.5µM thus suggesting the occurrence of herb-drug interaction, given that 
CYP1A2 is solely responsible for the metabolism and disposition of almost all drugs 
currently used (Wang et al., 2010).  
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Therefore, in recent time, modulation of the activity of CYP1A2 by dietary 
phytochemicals such as flavonoids and elucidation of the structure of flavonoids that 
are responsible in herb-drug interaction have gain worldwide attention. Zhai et al. 
(1998) reported flavone and five hydroxylated derivatives of flavone showed 
different potencies and selectivities on inhibition of CYP1A enzymes. Mitragyna 
speciosa alkaloid extract showed moderate inhibition towards CYP1A2 with an IC50 
value of 39µg/mL (Kong et al., 2011). According to Appiah-Opong et al. (2007), 
curcumin, a polyphenolic component of tumeric, inhibited CYP1A2 competitively 
with an IC50 value of 40.0µM. Kuo et al., (2004) stated that flavonols inhibited 
CYP1A enzyme in the decreasing order of aglycone >> monoglycoside > 
diglycoside. CYP1A2 metabolizes important medicines as listed in Table 2.3, 
therefore, suggesting that interaction between medicines and herbal extract that 
metabolize by the same enzyme may increase the plasma concentration of those 
particular medicines that if it is taken concurrently.
 
 
